Public | |
Traded as | : BSX S&P 500 Component |
Industry | Medical equipment |
Founded | 1979 |
Headquarters | Marlborough, Massachusetts, United States |
Key people
|
John Abele, Founder & Director Emeritus Peter Nicholas, Founder & Director Emeritus Michael Mahoney, President, Chairman and CEO |
Revenue | $ 7.477 billion (2014) |
Total assets | $ 3.471 billion (2015) |
Total equity | $ 16.83 billion (2014) |
Number of employees
|
25,000 (December 2011) |
Website | www.bostonscientific.com |
The Boston Scientific Corporation (abbreviated BSC) is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Boston Scientific is primarily known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD).
Boston Scientific's main competitors are Johnson and Johnson, Medtronic, St. Jude Medical, and the Abbott Vascular division of Abbott Laboratories.
Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.
The company went public through an IPO on May 19, 1992.
The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.
On April 21, 2006, the company acquired longtime competitor Guidant for $27.2 billion. The former Guidant was split between BSC and Abbott Laboratories.